A new type of vaccine that can be stored at warmer temperatures, removing the need for refrigeration, has been developed for mosquito-borne virus Chikungunya in a major advance in vaccine technology.
The findings, published in Science Advances today [Wednesday 25 September], reveal exceptionally promising results for the Chikungunya vaccine candidate, which has been engineered using a synthetic protein scaffold that could revolutionise the way vaccines are designed, produced and stored.
Infectious diseases continue to plague populations worldwide. Among the means at our disposal to counter this threat, vaccination has proven to be exceptionally powerful. Smallpox has been eradicated, measles, polio and tetanus constrained from the world by vaccination. However, severe challenges to human health persist, evidenced by epidemics caused by Ebola, Zika and others. This is particularly severe in developing countries which often lack adequate infrastructure and resources to prevent or manage outbreaks, bringing about disruption and damage in affected communities and massive economic shortfall.
A recent example is Chikungunya, a virus transmitted by the bite of an infected mosquito. The disease causes crippling headache, vomiting, swelling of limbs and can lead to death. Even if a fever ends abruptly, chronic symptoms such as intense joint pain, insomnia and extreme prostration remain. Formerly confined to sub-Saharan Africa, Chikungunya has recently spread worldwide as its mosquito host leaves its natural habitat due to deforestation and climate change, with recent outbreaks in USA and Europe causing alarm.
Researchers from the University of Bristol and the French National Centre for Scientific Research (CNRS) in Grenoble, France, teamed up with computer technology giant Oracle to find a way to make vaccines that are thermostable (able to withstand warm temperatures), can be designed quickly and are easily produced.
“We were working with a protein that forms a multimeric particle resembling a virus but is completely safe, because it has no genetic material inside, said Pascal Fender, expert virologist at CNRS. “Completely by chance, we discovered that this particle was incredibly stable even after months, without refrigeration.”
“This particle has a very flexible, exposed surface that can be easily engineered, added Imre Berger, Director of the Max Planck-Bristol Centre for Minimal Biology in Bristol. “We figured that we could insert small, harmless bits of Chikungunya to generate a virus-like mimic we could potentially use as a vaccine.”
To validate their design, the scientists employed cryo-electron microscopy, a powerful new technique recently installed in Bristol’s state-of-the-art microscopy facility headed by Christiane Schaffitzel, co-author of the study. Cryo-EM yields very large data sets from which the structure of a sample can be determined at near atomic resolution, requiring massive parallel computing.
Enabled by Oracle’s high-performance cloud infrastructure, the team developed a novel computational approach to create an accurate digital model of the synthetic vaccine. University of Bristol IT specialists Christopher Woods and Matt Williams, together with colleagues at Oracle, implemented software packages seamlessly on the cloud in this pioneering effort. Christopher explained: “We were able to process the large data sets obtained by the microscope on the cloud in a fraction of the time and at much lower cost than previously thought possible.”
“Researchers have had a long tradition of building and installing their own super computers on-premises, but cloud computing is allowing them to run large data sets in record time, with fast connectivity and low latency. This is helping them crunch data and make scientific breakthroughs much faster. Going forward, technologies like machine learning and cloud computing will play a significant part in the scientific world, and we are delighted we could help the researchers with this important discovery,” added Phil Bates, leading cloud architect at Oracle.
The particles the scientists designed yielded exceptionally promising results in animal studies, soundly setting the stage for a future vaccine to combat Chikungunya disease.
“We were thoroughly delighted,” continued Imre Berger. “Viruses are waiting to strike, and we need to have the tools ready to tackle this global threat. Our vaccine candidate is easy to manufacture, extremely stable and elicits a powerful immune response. It can be stored and transported without refrigeration to countries and patients where it is most needed. Intriguingly, we can now rapidly engineer similar vaccines to combat many other infectious diseases just as well.”
“It really ticks a lot of boxes,” concluded Fred Garzoni, founder of Imophoron Ltd, a Bristol biotech start-up developing new vaccines derived from the present work. “Many challenges in the industry require innovative solutions, to bring powerful new vaccines to patients. Matching cutting-edge synthetic biology with cloud computing turned out to be a winner.”
The Latest on: Synthetic vaccines
via Google News
The Latest on: Synthetic vaccines
- Inputs of Macromolecular Engineering in the Design of Injectable Hydrogels Based on Synthetic Thermoresponsive Polymerson January 16, 2020 at 6:48 am
His current research focuses on the synthesis of polymer biomaterials for vaccine/drug delivery ... Injectable hydrogels can be made from natural and synthetic polymers. Originally, natural polymers ...
- Codagenix Raises $20M in Series B Fundingon January 13, 2020 at 1:16 pm
a broadly-protective influenza vaccine and an oncolytic virus therapy for triple negative breast cancer (TNBC). Led by CEO J. Robert Coleman, PhD, MBA, Codagenix is a clinical stage synthetic biology ...
- Influenza Vaccines Triggers Immune System Response in Tumorson January 13, 2020 at 8:55 am
Only 1 flu shot with a synthetic adjuvant had no antitumor effect; it also maintained B cells that suppress an immune response. When the adjuvant was removed from the vaccine, it became effective.
- Codagenix Raises $20 Million in Series B Funding for Continued Development of RSV, Influenza and Oncolytic Virus Productson January 13, 2020 at 8:07 am
About Codagenix Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral ...
- Flu shot may help fight cancer, new study showson January 12, 2020 at 3:13 am
One flu shot with a synthetic adjuvant (an immune modifier ... When the adjuvant was removed from the vaccine, it became effective. Similarly, when the B cells were removed, the vaccine also ...
- The End Of The Flu: Can We Immunize The World Against A Seasonal Killer?on January 10, 2020 at 6:42 am
We’re entering a deadly time of year, as flu traverses the globe and ends hundreds of thousands of lives. It need not be this way, and several synthetic biology projects are working to create ...
- Emergex Raises More Than US$11 Million in a Series A Round to Progress Its Pipeline of Set-Point Vaccines for Infectious Diseaseson January 9, 2020 at 1:07 am
compared to traditional approaches that can take years to develop and scale vaccines for single pathogens. As purely synthetic vaccines with no biological components, Emergex's vaccines are much safer ...
- Vaccines & Vaccination Market Will Generate Massive Revenue in Coming Yearson January 8, 2020 at 12:34 pm
Global Vaccines & Vaccination Market Size, Status and Forecast 2019-2025 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and ...
- Can FDA-approved flu shots be repurposed as treatments for cancer?on January 7, 2020 at 2:22 am
Not all effective flu vaccines work on cancer Five different influenza shots for the 2017-2018 flu season were used in this research. Four were effective in achieving the same results in fighting ...
- Vaping and vaccines to forefront in 2019 healthcare debateson January 4, 2020 at 7:09 am
Strife over vaccines: There were rising rates in the region ... But despite these gains, the emergence of fentanyl — a powerful synthetic opioid now frequently added by dealers to heroin to make it ...
via Bing News